SEITO is dedicated to developing innovative immunotherapies for immune-mediated diseases, including autoimmune disorders, chronic inflammation, and transplant rejection. These conditions, which are both serious and lifelong, impact approximately 4% of the population in developed countries. Our approach focuses on engineering regulatory T (Treg) cell engagers (TREX) to precisely and safely activate Treg cells, helping to restore immune balance and prevent harmful self-targeted immune responses.

SEITO Biologics

Org chart

Teams

Offices